A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma
Status:
Terminated
Trial end date:
2017-02-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to compare the efficacy and safety of masitinib 6 mg/kg/day in
combination with bortezomib and dexamethasone to placebo in combination with bortezomib and
dexamethasone in the treatment of patients with relapsing multiple myeloma who have received
one previous therapy.